Abstract: Complexes containing a labeled polypeptide and an antibody, and the use of such complexes as research, diagnostic, and clinical tools, are described herein.
Type:
Grant
Filed:
November 8, 2022
Date of Patent:
April 30, 2024
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Inventors:
Wendy K. Nevala, Svetomir N. Markovic, John T. Butterfield, Daniel J. Knauer
Abstract: Peptide analogues of ?-amyloid and methods of using said analogues for neuroprotection are described herein. The ?-amyloid peptide analogues have a sequence that is at least 50% identical to an N-terminal ?-amyloid core fragment. A pharmaceutical composition of the ?-amyloid peptide analogues in a pharmaceutically acceptable carrier can be administered to a subject for neuromodulation. The ?-amyloid peptide analogues, while lacking neurotoxicity, effectively provides for protective activity against ?-amyloid toxicity.
Type:
Grant
Filed:
August 15, 2017
Date of Patent:
April 30, 2024
Assignees:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, UNIVERSITY OF HAWAII
Inventors:
Robert A. Nichols, Kelly Forest, Victor J. Hruby
Abstract: Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.
Abstract: The present disclosure provides a basal ganglia-on-a-chip for screening therapeutic agents for brain and nervous system diseases and a method for fabricating the same. The present invention provides a method for screening therapeutic agents for dopamine-dependent brain and nervous system diseases by using a basal ganglia-on-a-chip. When the basal ganglia-on-a-chip of the present invention is used in the effect evaluation of therapeutic agents for brain and nervous system diseases, the effect evaluation of therapeutic candidate substances can be economically and promptly carried out compared with an existing technique.
Type:
Grant
Filed:
May 30, 2019
Date of Patent:
April 16, 2024
Assignee:
SOGANG UNIVERSITY RESEARCH FOUNDATION
Inventors:
Jeong-Woo Choi, Won Jun Lee, Jae Wook Shin
Abstract: Humanized mouse models and methods are provided for determining whether administration of an immunomodulatory drug likely elicits a severe cytokine release syndrome in a human. Humanized mouse models and methods are also provided for determining the immunotoxicity in a human of a drug candidate or of drug combinations.
Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.
Abstract: The present invention is directed to a monoclonal mouse or humanized ROR1 antibody, or a single-chain variable fragment (scFv). The present invention is also directed to a mouse or humanized ROR1 chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain.
Abstract: The present invention provides a tumor blood marker and a use thereof. Specifically, the present invention provides a use of a reagent, which is used to detect GAPDH in a blood sample, in a preparation of a detecting composition for tumor screening, risk evaluation of tumor development in subjects, distinction of tumor progression stages, identification of therapeutic efficacy of tumor and/or risk analysis of tumor progression. The present invention also provides a kit and a method for detecting GAPDH concentrations in blood samples.
Abstract: Disclosed is a method for producing a spherical neural mass having suppressed teratoma formation. When using the spherical neural mass produced according to the method of the present disclosure, the purity of the neuronal progenitor cells may be improved, the teratoma formation may be suppressed, and the viability and recovery percentage of the cell may be increased.
Abstract: The invention relates generally to a process for isolating subpopulations of EVs to identify biomarkers useful identifying, determining the progression of, and/or prognosing a disease, including a neurological disease. More particularly, the present invention relates to detection technology of various exosomal biomarkers including proteins, protein modifications, sugars, RNA, DNA, lipids, and metabolites, and combinations thereof.
Type:
Grant
Filed:
July 12, 2018
Date of Patent:
February 13, 2024
Assignee:
Exosome Diagnostics, Inc.
Inventors:
Mia Sher, Erez Eitan, Christine Coticchia, Johan Karl Olov Skog, Robert Kitchen, Seth Yu
Abstract: Provided herein are compositions, methods, kits and systems for treating cells, tissues and subjects to alter age-related biology (e.g., to study or to treat age-related diseases and conditions). In particular, provided herein are compositions, methods, and uses for inhibition or modification of sialic acid or its cognate receptor to restore phagocytosis in aged cells.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
February 6, 2024
Assignees:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Inventors:
Anton Wyss-Coray, John Vincent Pluvinage, Michael C. Bassik, Michael Haney, Benjamin Smith, Carolyn Bertozzi
Abstract: Disclosed are methods for treating or preventing or delaying outset of Alzheimer's disease (AD) in a subject by targeting the novel pathway STAT1-CH25H in AD pathogenesis, specifically by administering to the subject a pharmaceutically effective amount of a STAT1 inhibitor, a CH25H inhibitor, or a 25-OHC inhibitor, for example, a 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor such as simvastatin.
Abstract: The present disclosure provides methods for classifying a cell as abnormal based on HD5 protein detection as well as methods for predicting prognosis of a subject with Crohn's disease based on HD5 protein detection.
Abstract: This invention is generally related to modified peptidic oligomers that have an increased ability to reach the cytosol or nucleus. In some embodiments, the modified peptidic oligomer molecules deliver an associated cargo molecule to the cytosol or nucleus. Other embodiments of the invention relate to modified peptidic oligomer fusion molecules that reach the cytosol or nucleus.
Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
Type:
Grant
Filed:
December 14, 2020
Date of Patent:
December 26, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
William H. Frey, II, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa, III
Abstract: Provided are methods and compositions from reprogramming human glial cells into human neurons. The reprogramming is achieved using combinations of compounds that can modify signaling via Transforming growth factor beta (TGF-?), Bone morphogenetic protein (BMP), glycogen synthase kinase 3 (GSK-3), and ?-secretase/Notch pathways. The reprogramming is demonstrated using groups of three or four compounds that are chosen from the group thiazovivin, LDN193189, SB431542, TTNPB, CHIR99021, DAPT, VPA, SAG; purmorphamine. Reprogramming is demonstrated using the group of LDN193189/CHIR99021/DAPT, the group of B431542/CHIR99021/DAPT, the group of LDN193189/DAPT/SB431542, the group of LDN193189/CHIR99021/SB431542, a three drug combination of SB431542/CHIR99021/DAPT. Reprogramming using functional analogs of the compounds is also provided, as are pharmaceutical formulations that contain the drug combinations.
Type:
Grant
Filed:
August 9, 2021
Date of Patent:
December 26, 2023
Assignee:
The Penn State Research Foundation
Inventors:
Gong Chen, Gang-Yi Wu, Lei Zhang, Jiu-Chao Yin, Hana Yeh, Ning-Xin Ma, Grace Lee
Abstract: The present invention provides a method of treating a tau-mediated cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-Tau antibody and an effective amount of an OGA inhibitor.
Type:
Grant
Filed:
January 5, 2021
Date of Patent:
December 12, 2023
Assignee:
Eli Lilly and Company
Inventors:
Mansuo Lu Hayashi, Michael Carl Irizarry, Hugh Nuthall
Abstract: A method for diagnosing a disease can include detecting, in a sample from a patient, an autoantibody binding to Septin-7. A polypeptide comprising Septin-7 or a variant thereof can be used for the diagnosis of a disease. Preferably, the polypeptide is used to detect an autoantibody binding to Septin-7 in a sample. A kit is useful for the diagnosis of a disease. The kit may include a polypeptide that includes Septin-7 or a variant thereof or a medical device that includes a polypeptide that includes Septin-7 or a variant thereof and an autoantibody to Septin-7.
Type:
Grant
Filed:
December 8, 2020
Date of Patent:
December 5, 2023
Assignees:
EUROIMMUN Medizinische Labordiagnostika AG, Mayo Foundation for Medical Education and Research
Inventors:
Ramona Miske, Madeleine Scharf, Lars Komorowski, Yvonne Denno, Stefanie Hahn, Christiane Radzimski, Mandy Unger, Andrew McKeon, Sean Pittock, Thomas Kryzer, Vanda Lennon, Josephe Honorat
Abstract: A method of generating a cellular model of Alzheimer's disease (AD) comprises integrating AD related gene to hiPSC to induce increased beta secretase and/or Abeta 42 peptides, and the cellular model of Alzheimer's disease (AD) is prepared by the method.